Literature DB >> 27162687

Where do we go from here? Reappraising the data on anticoagulation in pulmonary arterial hypertension.

Meghan M Cirulis1, John J Ryan1.   

Abstract

The use of anticoagulation as part of the treatment regimen in pulmonary arterial hypertension (PAH) remains a topic of debate. A recently published analysis of anticoagulation use in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) study offers conflicting conclusions regarding the benefit of this therapeutic strategy. There remains no robust randomized trial in PAH weighing the risks versus benefits of including anticoagulation in treatment regimens, leaving clinicians to surmise value in individual patients. Reexamination of available data may help to provide guidance on this controversial topic in the absence of future dedicated investigations.

Entities:  

Keywords:  Warfarin; prostacyclins; pulmonary hypertension; randomized registry trial; vitamin K antagonists (VKA)

Year:  2016        PMID： 27162687      PMCID： PMC4842822          DOI： 10.21037/jtd.2016.03.67

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


  62 in total

1.  Design of the REVEAL registry for US patients with pulmonary arterial hypertension.

Authors:  Michael D McGoon; Abby Krichman; Harrison W Farber; Robyn J Barst; Gary E Raskob; Theodore G Liou; Dave P Miller; Kathy Feldkircher; Scott Giles
Journal:  Mayo Clin Proc       Date:  2008-08       Impact factor: 7.616

2.  Evolving epidemiology of pulmonary arterial hypertension.

Authors:  Thenappan Thenappan; John J Ryan; Stephen L Archer
Journal:  Am J Respir Crit Care Med       Date:  2012-10-15       Impact factor: 21.405

Review 3.  Oral anticoagulation for pulmonary arterial hypertension: systematic review and meta-analysis.

Authors:  Daniel Caldeira; Maria José Loureiro; João Costa; Fausto J Pinto; Joaquim J Ferreira
Journal:  Can J Cardiol       Date:  2014-04-25       Impact factor: 5.223

4.  Altered platelet function in patients on continuous infusions of epoprostenol.

Authors:  D A Yardumian; S J Machin
Journal:  Lancet       Date:  1984-06-16       Impact factor: 79.321

5.  Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension.

Authors:  Ivo R Henkens; Thomas Hazenoot; Anco Boonstra; Menno V Huisman; Anton Vonk-Noordegraaf
Journal:  Eur Respir J       Date:  2012-08-30       Impact factor: 16.671

6.  Portopulmonary hypertension: a report from the US-based REVEAL Registry.

Authors:  Michael J Krowka; Dave P Miller; Robyn J Barst; Darren Taichman; Raed A Dweik; David B Badesch; Michael D McGoon
Journal:  Chest       Date:  2011-07-21       Impact factor: 9.410

7.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.

Authors:  S Rich; E Kaufmann; P S Levy
Journal:  N Engl J Med       Date:  1992-07-09       Impact factor: 91.245

8.  New predictors of outcome in idiopathic pulmonary arterial hypertension.

Authors:  Steven M Kawut; Evelyn M Horn; Ketevan K Berekashvili; Robert P Garofano; Rochelle L Goldsmith; Allison C Widlitz; Erika B Rosenzweig; Diane Kerstein; Robyn J Barst
Journal:  Am J Cardiol       Date:  2005-01-15       Impact factor: 2.778

9.  Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

Authors:  Karen M Olsson; Marion Delcroix; H Ardeschir Ghofrani; Henning Tiede; Doerte Huscher; Rudolf Speich; Ekkehard Grünig; Gerd Staehler; Stephan Rosenkranz; Michael Halank; Matthias Held; Tobias J Lange; Juergen Behr; Hans Klose; Martin Claussen; Ralf Ewert; Christian F Opitz; C Dario Vizza; Laura Scelsi; Anton Vonk-Noordegraaf; Harald Kaemmerer; J Simon R Gibbs; Gerry Coghlan; Joanna Pepke-Zaba; Uwe Schulz; Matthias Gorenflo; David Pittrow; Marius M Hoeper
Journal:  Circulation       Date:  2013-09-30       Impact factor: 29.690

10.  Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland.

Authors:  Yi Ling; Martin K Johnson; David G Kiely; Robin Condliffe; Charlie A Elliot; J Simon R Gibbs; Luke S Howard; Joanna Pepke-Zaba; Karen K K Sheares; Paul A Corris; Andrew J Fisher; James L Lordan; Sean Gaine; J Gerry Coghlan; S John Wort; Michael A Gatzoulis; Andrew J Peacock
Journal:  Am J Respir Crit Care Med       Date:  2012-07-12       Impact factor: 21.405
View more
  2 in total

1.  Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension.

Authors:  Arun Jose; Hind Rafei; Jalil Ahari
Journal:  Pulm Circ       Date:  2017-07-05       Impact factor: 3.017

2.  Pulmonary arterial hypertension patients display normal kinetics of clot formation using thrombelastography.

Authors:  Mengyun Lu; Kevin P Blaine; Ann Cullinane; Courtney Hall; Alina Dulau-Florea; Junfeng Sun; Herman F Chenwi; Grace M Graninger; Bonnie Harper; Keshia Thompson; Janell Krack; Christopher F Barnett; Samuel B Brusca; Jason M Elinoff; Michael A Solomon
Journal:  Pulm Circ       Date:  2021-06-24       Impact factor: 3.017
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.